April 2014 in “The FASEB Journal” Testosterone reduces knee movement, while flutamide and finasteride increase it.
31 citations
,
January 1981 in “Pharmacology & Therapeutics” Oral retinoids are effective for treating severe skin disorders but have reversible side effects and risks for pregnant women.
July 2025 in “American Journal on Addictions” Using 5-alpha reductase inhibitors may lower the risk of opioid addiction in men taking opioids.
1 citations
,
February 2013 in “Steroids” Bone mineral and minocycline boost bone cell growth, aiding healing.
19 citations
,
March 2018 in “Expert Opinion on Drug Safety” Most treatments for spondyloarthritis are safe, but monitoring and careful selection based on patient risks are important.
38 citations
,
October 2005 in “Expert opinion on therapeutic patents” Selective androgen receptor modulators (SARMs) are a promising type of drug for various health conditions due to their targeted actions.
5 citations
,
February 2025 in “Pediatric Dermatology” Ritlecitinib was generally well tolerated in children with alopecia areata.
January 2016 in “대한피부과학회지” Bortezomib chemotherapy can cause temporary skin rashes.
13 citations
,
January 1999 in “Postgraduate Medicine” New drugs for rheumatoid arthritis show improvement but have side effects and are not a cure.
March 2026 in “Journal of Clinical Oncology” Using 5-α-reductase inhibitors before treatment improves outcomes for patients with metastatic renal cell carcinoma.
3 citations
,
August 2020 in “Urology Journal” Using 5-alpha reductase inhibitors may increase the risk of mild depression.
18 citations
,
January 2001 in “Annual Reports in Medicinal Chemistry” Selective Androgen Receptor Modulators (SARMs) are drugs that can control the effects of androgens in different tissues, potentially having fewer side effects and promising for treating various conditions.
53 citations
,
October 1993 in “Drug Safety” Oral retinoids can cause side effects ranging from mild to severe, including birth defects, and require careful monitoring and contraception.
15 citations
,
January 2025 in “Journal of the European Academy of Dermatology and Venereology” Ritlecitinib is effective and safe for treating alopecia areata, promoting significant hair regrowth.
October 2025 in “Dermatology and Therapy” Ritlecitinib is being tested for effectiveness and safety in treating severe alopecia areata.
5 citations
,
August 2021 in “Frontiers in Cell and Developmental Biology” DHEA boosts bone cell growth and differentiation in elderly stem cells.
108 citations
,
November 1980 in “British Journal of Dermatology” Oral retinoids are effective for various skin conditions but have side effects and should not be used during pregnancy.
50 citations
,
December 2006 in “Bone” Exemestane may protect bones by stimulating osteoblast growth through androgen-related pathways.
September 2025 in “Value in Health”
11 citations
,
October 2019 in “Cancers” Spironolactone may make some cancer treatments more effective by blocking a protein that helps cancer cells survive.
March 2025 in “Scientific Reports” Higher doses of 5α-reductase inhibitors may lower mortality risk, but low doses increase it.
29 citations
,
January 2003 in “KARGER eBooks” HVDRR is caused by VDR gene mutations, leading to vitamin D resistance, treatable with high calcium doses, but alopecia remains permanent.
Ritlecitinib significantly regrows scalp hair in people with alopecia areata.
6 citations
,
August 2021 in “Clinical Epidemiology” Men using 5-alpha reductase inhibitors for prostate issues may have a slightly higher risk of blood clots.
1 citations
,
November 2023 in “SKIN The Journal of Cutaneous Medicine” November 2024 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib effectively reduces severe hair loss in alopecia areata over 24 months.
July 2020 in “bioRxiv (Cold Spring Harbor Laboratory)” The structure of SRD5A reveals how it reduces steroids, aiding drug design for related health conditions.
January 2024 in “American journal of clinical dermatology” Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.
July 2026 in “Journal of Enzyme Inhibition and Medicinal Chemistry” Improved CRBN ligands make protein degraders more effective and drug-like.
June 2026 in “Pharmaceuticals” 5α-Reductase inhibitors, like finasteride, can cause serious, persistent side effects not always listed in official drug information.